Miltefosine-d4
Miltefosine-d4 (HePC-d4) is deuterium labeled Miltefosine. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity[1][2][3][4]. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT) [5][6].
Product Specifications
Product Name Alternative
HePC-d4; Hexadecyl phosphocholine-d4
UNSPSC
12352211
Target
Akt; HIV; Isotope-Labeled Compounds; Parasite
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Others; PI3K/Akt/mTOR
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Smiles
CCCCCCCCCCCCCCCCOP(OC([2H])(C([2H])([N+](C)(C)C)[2H])[2H])([O-])=O
Molecular Formula
C21H42D4NO4P
Molecular Weight
411.59
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Uberall F, et al. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991 Feb 1;51 (3) :807-12.|[3]Eissa MM, et al. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS One. 2015 Nov 17;10 (11) :e0141788|[4]Chugh P, et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology. 2008 Jan 31;5:11|[5]de Freitas-Junior PR, et al. Effects of miltefosine on the proliferation, ultrastructure, and phospholipid composition of Angomonas deanei, a trypanosomatid protozoan that harbors a symbiotic bacterium. FEMS Microbiol Lett. 2012 Aug;333 (2) :129-37.|[6]Bhatt AP, et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010 Jun 3;115 (22) :4455-63.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
